• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Influencing factors of antibody response after 2 doses of inactivated COVID-19 vaccine among adults aged ≥18 years in Chongqing, China: A cross-sectional serological study.中国重庆 18 岁及以上成年人接种 2 剂灭活 COVID-19 疫苗后抗体反应的影响因素:一项横断面血清学研究。
Medicine (Baltimore). 2024 Oct 18;103(42):e40075. doi: 10.1097/MD.0000000000040075.
2
Factors influencing antibody response after COVID-19 recombinant protein vaccination in adults: A cross-sectional observational study, in Chongqing, China.影响中国重庆成年人 COVID-19 重组蛋白疫苗接种后抗体反应的因素:一项横断面观察性研究。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2389602. doi: 10.1080/21645515.2024.2389602. Epub 2024 Aug 22.
3
Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.比较中国 HIV 感染者和 HIV 阴性个体对 SARS-CoV-2 灭活疫苗的免疫反应:一项横断面研究。
Viruses. 2022 Jan 28;14(2):277. doi: 10.3390/v14020277.
4
Clinical and laboratory features in health care volunteers with inactivated SARS-CoV-2 vaccination.接种灭活 SARS-CoV-2 疫苗的医护志愿者的临床和实验室特征。
Turk J Med Sci. 2023 May 25;53(5):1185-1193. doi: 10.55730/1300-0144.5684. eCollection 2023.
5
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.一种灭活的严重急性呼吸综合征冠状病毒 2 疫苗(BBIBP-CorV)的安全性和免疫原性:一项随机、双盲、安慰剂对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Jan;21(1):39-51. doi: 10.1016/S1473-3099(20)30831-8. Epub 2020 Oct 15.
6
Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.人类针对灭活的 SARS-CoV-2 疫苗的 IgM 和 IgG 反应。
Curr Med Sci. 2021 Dec;41(6):1081-1086. doi: 10.1007/s11596-021-2461-8. Epub 2021 Nov 6.
7
Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study.在接受疾病修正治疗的多发性硬化症患者中,国药(BBIBP-CorV)SARS-CoV-2 疫苗的免疫原性、临床疗效和安全性:一项前瞻性队列研究。
BMC Neurol. 2024 Aug 20;24(1):291. doi: 10.1186/s12883-024-03793-y.
8
Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.与两种新冠病毒灭活疫苗在初级系列接种后 12 个月诱导的中和抗体水平相关的因素。
Front Immunol. 2022 Sep 9;13:967051. doi: 10.3389/fimmu.2022.967051. eCollection 2022.
9
Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.接种 BBIBP-CorV 作为基础免疫后加强接种异源 Ad26.COV2.S 对 SARS-CoV-2 感染的效果:一项 1 年随访的 1/2 期开放标签试验。
Vaccine. 2024 Jul 25;42(19):3999-4010. doi: 10.1016/j.vaccine.2024.05.010. Epub 2024 May 13.
10
Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study.序贯接种新冠灭活疫苗和重组蛋白疫苗对老年人的安全性、免疫原性和保护效果:一项前瞻性纵向研究。
Signal Transduct Target Ther. 2024 May 13;9(1):129. doi: 10.1038/s41392-024-01846-9.

中国重庆 18 岁及以上成年人接种 2 剂灭活 COVID-19 疫苗后抗体反应的影响因素:一项横断面血清学研究。

Influencing factors of antibody response after 2 doses of inactivated COVID-19 vaccine among adults aged ≥18 years in Chongqing, China: A cross-sectional serological study.

机构信息

Expand Program on Immunization, Chongqing Center for Disease Control and Prevention, Chongqing, China.

出版信息

Medicine (Baltimore). 2024 Oct 18;103(42):e40075. doi: 10.1097/MD.0000000000040075.

DOI:10.1097/MD.0000000000040075
PMID:39432616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11495710/
Abstract

The study aimed to explore the influencing factors after 2 doses of inactivated COVID-19 vaccines (Sinopharm/BBIBP-CorV) in the real world. We conducted a cross-sectional serological study involving 316 volunteers aged ≧ 18 years from 7 vaccination hospitals in the Yubei districts, Yuzhong districts, and Jiulongpo districts of Chongqing. Serum samples were obtained about 1 month after 2 dose vaccination, and Nabs were tested using the pseudovirus-based neutralizing assay. Chi-square or Fisher exact tests were used to analyze the seropositive rates, while the Kruskal-Wallis H or Mann-Whitney U tests were used to analyze differences in Nabs level among stratified groups. Logistic regression analyses were conducted to identify the influencing factors. The results showed that seropositive rates was 76.27% and the GMT was 26.13 (95% CI: 23.03-29.66) after 2 doses of COVID-19 inactivated vaccination. The risk of being seropositive in 18 to 29, 30 to 39, 40 to 49, 50 to 59, and 60 to 69 years were 12.808-fold, 8.041-fold, 7.818-fold, 6.275-fold, 1.429-fold compared with the people aged ≥ 70 years (P < .05), and the risk of being seropositive of intervals 15 to 21 and 22 to 28 days were 0.273-fold and 0.286-fold compared with >28 days (P < .05), respectively. In conclusion, age may be a risk factor for reduced antibody production, and longer vaccination intervals-may be a protective factor that increases antibody production. These findings contribute to informing future vaccination strategies.

摘要

本研究旨在探索 2 剂灭活 COVID-19 疫苗(国药/BBIBP-CorV)在真实世界中的影响因素。我们进行了一项横断面血清学研究,纳入了来自重庆市渝北区、渝中区和九龙坡区的 7 家接种医院的 316 名年龄≥18 岁的志愿者。在 2 剂接种后约 1 个月采集血清样本,并使用假病毒中和测定法检测 Nabs。采用卡方检验或 Fisher 确切检验分析血清阳性率,采用 Kruskal-Wallis H 检验或 Mann-Whitney U 检验分析分层组中 Nabs 水平的差异。采用 logistic 回归分析识别影响因素。结果显示,2 剂 COVID-19 灭活疫苗接种后的血清阳性率为 76.27%,GMT 为 26.13(95%CI:23.03-29.66)。18-29、30-39、40-49、50-59 和 60-69 岁人群的血清阳性风险分别是≥70 岁人群的 12.808 倍、8.041 倍、7.818 倍、6.275 倍和 1.429 倍(P<.05),间隔 15-21 天和 22-28 天接种的血清阳性风险分别是间隔>28 天的 0.273 倍和 0.286 倍(P<.05)。总之,年龄可能是抗体产生减少的危险因素,较长的接种间隔可能是增加抗体产生的保护因素。这些发现有助于为未来的疫苗接种策略提供信息。